Versant unveils Light Horse with $62M and a partnership with Novartis

Kyle LaHucik

Senior Reporter

Versant Ventures’ latest biotech emerged on Thursday morning with a $62 million Series A from Bristol Myers Squibb, AbbVie and others, plus a partnership with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Versant unveils Light Horse with $62M and a partnership with Novartis

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Aiolos team reunites with $411M for new biotech with obesity drugs from China

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Resilience cuts 120 employees at a former bluebird gene therapy site

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Versant unveils Light Horse with $62M and a partnership with Novartis